CLOs on the Move

Thrasos Therapeutics

www.thrasos.com

 
Thrasos is a private, clinical-stage biotherapeutics company focused on delivering new solutions to individuals affected by kidney disease. The company's lead compound, THR-184 is currently being evaluated in a Phase 2 clinical study for the prevention of AKI in patients undergoing cardiac surgery. Thrasos is also developing compounds for diabetic nephropathy, a major cause of chronic kidney disease
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.thrasos.com
  • 2000 Rue Peel
    Montreal, AB CAN H3A 2W5
  • Phone: 514.940.2714

Executives

Name Title Contact Details

Similar Companies

Laureate Pharma

Laureate Pharma L.P. is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Relay Technology Management

Relay has developed a proprietary software solution for stakeholders of the biopharmaceutical technology licensing and development process.

Roswell Biotechnologies

Roswell Biotechnologies is a molecular electronics company transforming DNA sequencing with their latest platform, designed to deliver the disruptive performance required for future biomedical and industrial applications.

Novaseek Research

Novaseek is transforming how biomedical researchers access real-world hospital patient data and human biospecimens. Researchers rely on Novaseek to plan projects, and procure high quality biospecimens and clinical data needed to power discovery. Increasing productivity and de-risking projects across R&D enterprise begins with NovaSeek!

CymaBay

CymaBay Therapeutics is a clinical-stage biopharmaceutical company located in the San Francisco Bay Area focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases. We are committed to developing breakthrough medicines that improve the lives of patients and their families. CymaBay was seeded with the assets from an earlier metabolic disease company in which more than $120M was invested to produce a robust pipeline.